Phospho-Lyn (Tyr507) (5B6) rabbit mAb
Product Overview
Description
Lyn, along with Btk, supports the abnormal growth and survival of neoplastic mast cells. Phosphorylated Lyn has been identified in these cancerous cells, along with phosphorylated Btk, Hck, and Stat5. Dasatinib, a chemotherapy drug used to treat leukemia, is a tyrosine kinase inihibitor that binds directly to Lyn in neoplastic cells. Lyn and Btk have also been shown to be involved in IgE receptor-dependent activation. Increased Lyn activity, detected by higher amounts of phospho Lyn, has been demonstrated in breast cancer cell lines. This is likely mediated through effects of upstream regulators of Lyn, rather than mutations in Lyn itself.
Product Details
Specification | Description |
---|---|
Applications | Flow Cytometry, WB |
Clone | LynY507-5B6 |
Format | Unconjugated |
Validated Reactivity | Human, Mouse |
Cross Reactivity | Predicted to work with mouse, rat and other homologues. |
Detection | Anti-Rabbit IgG |
Clonality | Monoclonal |
Immunogen | A synthetic phospho-peptide corresponding to residues surrounding Tyr507 of human phospho Lyn |
Formulation | 1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA |
Isotype | Rabbit IgGk |
Preparation | Protein A+G |
Recommended Usage | 1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information. |
Storage | -20ºC |
Pseudonyms | Tyrosine-protein kinase Lyn, Lck/Yes-related novel protein tyrosine kinase, V-yes-1 Yamaguchi sarcoma viral related oncogene homolog, p53Lyn, p56Lyn, JTK8 |
Uniprot ID | P07948 |
References | Gleixner KV, Mayerhofer M, Cerny-Reiterer S et al. (2011) Blood. 28: 1077-1086. Choi Y, Bocanegra M, Kwon MJ et al. (2010) Molecular and Cellular Pathology. 70: 2296-2306. |
Images

Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNα + IL-4 + pervanadate (green) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01µg/mL. Cat. #2416.

Peptide blocking flow cytometric analysis of Jurkat cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFNα + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01µg/mL. Cat. #2416.

Flow cytometric analysis of C2C12 cells secondary antibody only negative control (blue) or treated with imatinib (red) or with pervanadate (green) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01µg/mL. Cat. #2416.

Western blot analysis of extracts of HeLa cells treated with H2O2. Cell lysates were ran on a SDS-PAGE gel, transferred to nitrocellulose membrane, blocked and non-treated (-) or treated with lambda phosphatase (+) and stained using anti-phosph-Lyn (Tyr507) 5B6 rabbit recombinant antibody #2416.

Western blot analysis of Hela cell extract, untreated or treated with H2O2 using Phospho-LYN(TYR507) antibody LYNY507-5B6 at 0.01 ug/mL. Cat. #2416.

Western blot analysis of HeLa cell extract, untreated or treated with H2O2 using 0.01 µg/mL Phospho-Lyn (Tyr507) antibody LynY507-5B6 Cat. #2416 or Company A antibody at 1 µg/mL (manufacturer’s recommended concentration) developed using the same exposure.